Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of isavuconazonium sulfate in adult Japanese patients with deep mycosis
jRCT2080223864Phase 3Completed
- Sponsor
- Asahi Kasei Corporation
- Start
- Apr 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of isavuconazonium in chronic pulmonary aspergillosis (CPA), invasive aspergillosis (IA), cryptococcosis and 2 more (2 arms), sponsored by Asahi Kasei Corporation. Started Apr 2018; status: completed.
02
Drugs
isavuconazonium
03
Conditions
chronic pulmonary aspergillosis (CPA)invasive aspergillosis (IA)cryptococcosismucormycosisDeep Mycoses
Beyond the preview
Go deeper on jRCT2080223864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223864.